Douglas R. Adkins

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

David G. Pfister, Sharon Spencer, David J. Adelstein et al. · Journal of the National Comprehensive Cancer Network · 2020 · 1.3K citations

Cancer Management, Pathology, Oncology +19

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert I. Haddad, Anne O’Neill, Guilherme Rabinowits et al. · The Lancet Oncology · 2013 · 735 citations

Advanced Head, Concurrent Chemoradiotherapy, Radiation Therapy +10

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister et al. · Journal of the National Comprehensive Cancer Network · 2018 · 620 citations · Full text

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami et al. · Journal of the National Comprehensive Cancer Network · 2022 · 505 citations

Nccn Guidelines® Insights, Surgical Oncology, Cancer Management +20